文献速递脑血管病外科神经重症

高渗盐水治疗动脉瘤性蛛网膜下腔出血后颅内压升高:一项系统综述

Hypertonic Saline for Increased Intracranial Pressure After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review.
PubMed 文献 · World Neurosurg · 2017-05-23

该系统综述纳入5项研究共175例动脉瘤性蛛网膜下腔出血(aSAH)患者,多数为世界神经外科医师联盟(WFNS)4-5级的重度患者,高渗盐水(HTS)浓度范围为3%-23.5%。多数研究发现HTS较基线或安慰剂降低颅内压(ICP),平均降低8.9 mm Hg(范围3.3-12.1 mm Hg);仅1项研究显示重度aSAH患者预后可能改善。作者认为现有证据提示HTS降低aSAH相关ICP升高的效果与甘露醇相当,但数据不足以推荐最佳且最安全的剂量浓度,也不足以判断HTS是否显著改善aSAH预后。

要点

  • 纳入5项研究共175例aSAH患者,多数为WFNS 4-5级重度患者。
  • HTS浓度范围为3%-23.5%,多数研究显示其较基线或安慰剂降低ICP,平均降低8.9 mm Hg(范围3.3-12.1 mm Hg)。
  • 仅1项研究显示重度aSAH患者预后可能改善;证据提示HTS降低ICP效果与甘露醇相当,但不足以推荐最佳且最安全的剂量浓度。

核心结论

  • 现有证据提示HTS降低aSAH相关ICP升高的效果与甘露醇相当,但数据不足以推荐最佳且最安全的剂量浓度,也不足以判断HTS是否显著改善aSAH预后。

研究设计与样本

  • 按照系统综述和Meta分析优先报告条目(PRISMA)指南进行的系统综述,纳入5项研究共175例患者。

主要发现

  • 纳入研究中的aSAH患者多数为重度患者(定义为WFNS 4级和5级),HTS浓度范围为3%-23.5%。
  • 多数研究发现HTS较基线或安慰剂降低ICP,HTS给药后ICP平均降低8.9 mm Hg(范围3.3-12.1 mm Hg)。
  • 仅1项研究显示重度aSAH患者预后可能改善。

关键数值与推荐

  • 主要结局为量化HTS产生的ICP降低及其对以任何标准化功能评分定义的临床结局的影响。
  • 次要结局包括HTS与甘露醇在降低ICP方面的比较、HTS对脑血管痉挛的影响,以及HTS的剂量浓度、输注速率、输注量、重复给药频率及重复给药的血钠/渗透压限度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出数据不足以推荐最佳且最安全的剂量浓度,也不足以判断HTS是否显著改善aSAH预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of hyperosmolar agents, such as mannitol or hypertonic saline (HTS), to control high intracranial pressure (ICP) in patients with traumatic brain injury has been well studied. However, the role of HTS in the management of aneurysmal subarachnoid hemorrhage (aSAH)-associated increased ICP is still unclear. METHODS: We performed a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The primary outcome of this review is to quantify ICP reduction produced by HTS and its effect on clinical outcomes defined by any standardized functional score. Secondary outcomes included HTS versus mannitol in ICP reduction, HTS effects on cerebral vasospasm, and HTS dose concentration, infusion rate, infusion volume, frequency of redosing, and serum sodium/osmolality limits for repeat dosing. RESULTS: Five studies were included in the review encompassing 175 patients. Studies on aSAH included mostly poor grade patients (defined as World Federation of Neurosurgical Societies grade 4 and 5). HTS concentrations ranged from 3%-23.5%. Most studies found that HTS decreased ICP when compared with either baseline or placebo. The mean decrease in ICP from HTS administration was 8.9 mm Hg (range: 3.3-12.1 mm Hg). Only 1 study showed possible improvement in poor grade aSAH outcomes. CONCLUSIONS: The current evidence suggests that HTS is as effective as mannitol at reducing increased ICP in aSAH. However, there is not enough data to recommend the optimal and safest dose concentration or whether HTS significantly improves outcomes in aSAH.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Pasarikovski CR, Alotaibi NM, Al-Mufti F, et al. Hypertonic Saline for Increased Intracranial Pressure After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. World Neurosurg. 2017. PMID: 28549643. doi:10.1016/j.wneu.2017.05.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。